Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
Open accessThe DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders having a high influence on social interactions. The number of approved treatments and clinical trials for ADHD have increased markedly during the recent decade. This analytical review provides a quantitative overview of the existing pharmacological and non-pharmacological methods of ADHD treatments investigated in clinical trials during 1999–2021. A total of 695 interventional trials were manually assessed from clinicaltrial.gov with the search term « ADHD», and trial data has been used for analysis. A clear majority of the studies investigated non-pharmacological therapies (∼80%), including many behavioral options, such as social skills training, sleep and physical activity interventions, meditation and hypnotherapy. Devices, complementary and other alternative methods of ADHD treatment are also gaining attention. The pharmacological group accounts for ∼20% of all the studies. The most common drug classes include central nervous system stimulants (e.g., methylphenidate hydrochloride, lisdexamfetamine dimesylate, amphetamine sulfate, mixed amphetamine salts, a combination of dexmethylphenidate hydrochloride and serdexmethylphenidate chloride), selective noradrenaline reuptake inhibitors (atomoxetine, viloxazine), and alpha2 adrenergic receptor agonists (guanfacine hydrochloride, clonidine hydrochloride). Several studies investigated antidepressants (e.g., bupropion hydrochloride, vortioxetine), and atypical antipsychotics (e.g., quetiapine, aripiprazole) but these are yet not approved by the FDA for ADHD treatment. We discuss the quantitative trends in clinical trials and provide an overview of the new drug agents and non-pharmacological therapies, drug targets, and novel treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627 · cited 1×
“Many of these neurotransmitters mediate their effects through G-protein coupled receptors (GPCRs) (Lagerstrom and Schioth, 2008; Hauser et al., 2017) and are transported by corresponding”
BackgroundSelf-citationCortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30269-4 · Cited by 1,716
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Structural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,492
Self-citationBrunoni, A. R., Nitsche, M. A., Bolognini, N., Bikson, M., Wagner, T., Merabet, L., Edwards, D. J., Valero-Cabre, A., Rotenberg, A., Pascual-Leone, A., et al. (2012) · Brain stimulation · doi:10.1016/j.brs.2011.03.002 · Cited by 1,445 · cited 1×
“It is a non-invasive, painless method of treatment that uses direct electrical currents to stimulate specific parts of the brain (Brunoni et al., 2012).”
MethodSonuga-Barke, E. J. S., Brandeis, D., Cortese, S., Daley, D., Ferrin, M., Holtmann, M., Stevenson, J., Danckaerts, M., van der Oord, S., Döpfner, M., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12070991 · Cited by 1,167 · cited 3×
“For other types of therapies evidence of efficacy from blinded assessments was needed (Sonuga-Barke et al., 2013).”
BackgroundMethodAttention deficit hyperactivity disorder
Thapar, A., & Cooper, M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00238-x · Cited by 1,043
Song, P., Zha, M., Yang, Q., Zhang, Y., Li, X., & Rudan, I. (2021) · Journal of Global Health · doi:10.7189/jogh.11.04009 · Cited by 896 · cited 1×
“The disorder affects around 5% of children and adolescents (Song et al., 2021) and 2.”
BackgroundExercise and Children’s Intelligence, Cognition, and Academic Achievement
Tomporowski, P. D., Davis, C. L., Miller, P. H., & Naglieri, J. A. (2008) · Educational Psychology Review · doi:10.1007/s10648-007-9057-0 · Cited by 874 · cited 1×
“to improvements in executive functions (Tomporowski et al., 2008; Wigal et al., 2013).”
Research works printed but not linked: 4
- APA (2013). Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA, USA: American Psychiatric Publishing.
- PDC-1421 - AdisInsight (2022). AdisInsight.springer.com. Available at: https://adisinsight.springer.com/drugs/800037456 (Accessed on October 23, 2022).
- Vallon Pharmaceuticals Inc (2021). Press release Announcement. Available at: https://www.vallon-pharma.com/news/vallon-pharmaceuticals-continues-advancement-of-pivotal-study-in-lead-development-program-adair-toward-potential-approval/ (accessed on August 26, 2021).
- Vallon Pharmaceuticals Inc (2022). Press release Announcement. Available at: https://www.vallon-pharma.com/news/vallon-pharmaceuticals-reports-additional-pharmacokinetic-and-pharmacodynamic-data-from-seal-study-of-adair/ (accessed on October 23, 2022).
Cited by
Items 101–145 of 145
ADHD – A GLOBAL CHALLENGE. ARE WE CLOSER TO THE IDEAL THERAPY?
Grzesik, K., Pilarczyk, K., Rabęda, A., Gawor, A., & Klepacz, N. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.4059
BUPROPION FOR ADHD: MECHANISMS OF ACTION AND ITS POTENTIAL AS AN ALTERNATIVE TREATMENT — A REVIEW
Narożniak, M., Czerwiec, B., Skowrońska-Borsuk, J., Borsuk, A., Pergoł, J. K., Wojtas, M. M., Pękacka, A. E., Borkowska, J., Krupa, Z., & Sposób, J. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3664
Uczniowie z ADHD w klasie. Poradnik dla nauczycieli
Słopień, A., Wolańczyk, T., Jerzak, M., Wydra, M., Olszewska, B., Rosa, A., & Kowalska, S. (2025) · doi:10.24131/9788368313819
Fakhari, A., Farahbakhsh, M., Azimian, A., Khameneh, A., Matinkia, M., & Aghajani, E. (2025) · Research Square · doi:10.21203/rs.3.rs-7468341/v1
Mustafayeva, A. M., Mustafayeva, A. M., Omargadjieva, F. S., Balaeva, M. V., Kobiz, A. S., Mironenko, K. V., Chinchiev, R. T., Budunova, F. M., & Girimova, B. U. (2025) · Journal Of Biochemical Technology · doi:10.51847/zej8pnykpw
“The development of higher mental functions may be delayed in children with ADHD, leading to decreased mental abilities and difficulty organizing activities (Nazarova et al ., 2022; Claussen et al ., 2024).”
Kamal, T. R., Shah, S., Ahmed, U., & Elhassan, H. (2025) · Cureus · doi:10.7759/cureus.96878
“Non-stimulant medications include selective noradrenaline reuptake inhibitors such as atomoxetine, which increase noradrenaline in the synapse, thereby improving prefrontal cortex function [6].”
InfluentialDas, S. R., Varadharasu, S., Singh, R., & Dixit, S. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1814_23
“[17] The first non-stimulant medication for ADHD was released in 2002, and others followed.”
Vankayala, P., Vankayala, R., Gumudavelli, S., Gumudavelli, S., & Kumar, S. D. (2025) · European journal of applied sciences · doi:10.14738/aivp.1306.19651
Sharma, R. H. (2024) · cIRcle (University of British Columbia) · doi:10.14288/1.0440957
Utilização da oxitocina no tratamento da Perturbação de Hiperatividade e Défice de Atenção
Teixeira, H. S. S. E. S. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/1ac4-sy53
Fischer, M., & Thomas, K. (2023) · Open University of Cape Town (University of Cape Town) · doi:10.25375/uct.21922413
The voices of adolescents with ADHD: Perceptions, Experiences, Attitudes and Expectations
Alves, C. B. A. C. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Karlström, A., & Thorsson, A. (2025) · Jonkoping University Library (Jönköping University)
Strothmann, S. (2024) · University Library of Skövde (University of Skövde)
Mor, T. (2025) · Universidad de Córdoba Insitutional Repository (Universidad de Córdoba)
Teixeira, A. T. M. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/9rdd-9n08
Farmácia da Madalena, Vila Nova de Gaia
Barbosa, A. S. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/yfmk-m455
Murteira, M. M. B. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Zhu, Y., Chen, D., & Chen, W. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1726801
“There is also a risk of dependence, and symptoms may recur after stopping medication (Nazarova et al., 2022).”
Maroone, C. (2026) · Issues in Mental Health Nursing · doi:10.1080/01612840.2026.2635920
“A review of the literature does indicate that bupropion may be beneficial in patients who may have contraindication to stimulant treatment, poor tolerability of stimulants, or decline due to concern over controlled substance or substance abuse concerns (Clark et al., 2023; Nazarova et al., 2022).”
Kato, M., Kan, S., Ichikawa, N., Takamura, M., & Okada, G. (2026) · Perceptual and Motor Skills · doi:10.1177/00315125261439049
Castellón, M. D., Angulo-Baena, E., Duque-Ruiz, V., García-Grey, L., de Ávila, A. P., & Teran-García, L. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.15s.16
Goulart, G. D., Goulart, G. D., & de Lucca, L. A. (2026) · Arquivos Catarinenses de Medicina · doi:10.63845/x1gh3q44
Garkuwa, N. N., Omede, J., & HAGGY, M. P. (2026) · International Journal of Assessment and Evaluation in Education · doi:10.70382/mejaee.v12i8.0123
Karimi, M., Ghasemzadeh, S., Ghasemzadeh, P., صالحی, ک., & Fami, F. S. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08293-6
“…these preferences stem from daily emotional strain, financial burden, social stigma, and a profound need for both emotional and practical support [59, 61, 62] Parents are showing more interest in different treatments like psychological therapies, neurofeedback, and nutritional interventions [63].”
Garkuwa, N. N., Omede, J., & HAGGY, M. P. (2026) · International Journal of African Innovation and Multidisciplinary Research · doi:10.70382/mejaimr.v12i2.0116
Dilweg, M. A., Jespers, W., Kasture, A. S., Liu, R., Mocking, T. A. M., Ploeg, J. G. V. D., Baselier, M. M., van Westen, G. J. P., Hummel, T., Sučić, S., et al. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00112b
“10 In case of selective dopamine reuptake inhibitors (DRIs), multiple inhibitors have been developed with the aim to treat psychostimulant use disorder or alleviate motor-related symptoms in Parkinson's disease which are a result of dopaminergic neurodegeneration.”
Reassessing ADHD Management: Integrating Gut Microbiome Insights and Herbal Nutritional Strategies
Elkalla, W. S., Salah, A. N., Mahmoud, N. A., AbdelRazek, M. M. M., Kotb, S. S., Elshami, N. H., AlFarsi, K., Waseem, A. M., Bogari, H. A., Malatani, R. T., et al. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00712-0 · Cited by 1
“ADHD is a multifaceted condition, and while its pathophys - iology has been linked to genetic, neurological, and environ - mental variables, the basic mechanisms remain unidentified [76].”
Medikamente zur Behandlung von ADHS und anderen Entwicklungsstörungen
Heiser, P., & Clement, H. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_10
Unmasking the Mystery: ADHD, Women, and Hormones
Galgani, C. J. L. (2026) · Clinical Journal for Nurse Practitioners in Women s Health · doi:10.1891/cjnpwh-2025-0052
Xiong, M., Jiang, S., Sun, Y., Cong, X., Zhao, N., & Wu, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1880554
“These interventions, however, may be time-consuming, require substantial parental and professional involvement, and be difficult to sustain, particularly for families with limited time and resources (4).”
Building the Mask: A Grounded Theory Study on Women and Gender Diverse AuDHD Adults
Swecker, K. (2026) · ThinkTech (Texas Tech University)
Zakiah, V., Hamudi, J. P., & Harni, H. (2026) · Journal La Medihealtico · doi:10.37899/journallamedihealtico.v7i4.3380
“The combination of these two therapies is expected to produce more optimal therapeutic effects because they work through different yet complementary physiological and psychological pathways (Niyonkuru et al., 2024; Yash et al., 2023; Nazarova et al., 2022).”
Azhar, S. R., Nanda, D. A., Wahananingtyas, N. L., & Setiyorini, E. (2026) · JURNAL ILMIAH KESEHATAN MASYARAKAT DAN SOSIAL · doi:10.59024/jikas.v4i3.2185
“Meskipun efektif dalam mengendalikan gejala utama, terapi farmakologis memiliki keterbatasan, seperti efek samping, kebutuhan penggunaan jangka panjang, dan tidak selalu memberikan perbaikan optimal pada fungsi kognitif (Nazarova et al., 2022).”
Yang, X., Liu, X., & Tan, M. (2026) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.70169
“Non-stimulant medications may be better tolerated in some patients with complex conditions (Nazarova et al. 2022).”
Cao, Y. (2026) · Lecture Notes in Education Psychology and Public Media · doi:10.54254/2753-7048/2026.36333
Kling, W. R. B. (2026) · Scholars Crossing (Liberty University)
Barnoon, T. (2026) · Oxford Journal of Student Scholarship · doi:10.65161/recqzk4pj4eaitv0t
Souza, H. F. A. D., & Figueiredo, M. B. G. D. A. (2026) · Revista JRG de Estudos Acadêmicos · doi:10.55892/jrg.v9i21.3788
Anàlisi de casos clínics de TDAH en població infanto juvenil
Martí, L. L. (2025) · Rovira & Virgili repository
AYURVEDIC MANAGEMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER- A CASE REPORT.
Sohini, S., Sheba, M. D., & Anilkumar, M., V (2026) · Kerala Journal of Ayurveda · doi:10.55718/kja.619
Pei, P., Lu, S., yu, W., Zhao, X., & Lin, J. (2026) · Twin Research and Human Genetics · doi:10.1017/thg.2026.10106
Hosseinpourfardi, A., Sahaf, S. M. S., Afzaljavan, F., Soltanifar, A., & Moharreri, F. (2026) · Brain and Behavior · doi:10.1002/brb3.71822
“Conventional treatment involves behavioral and pharmacological strategies, with stimulants, such as methylphenidate, central to management (Nazarova et al. 2022 ).”
Glaser, M., Dieterich, L., Ceslik, L., Schickardt, Z., Gätzner, S., Schmitt, L., Oberwinkler, H., Reining, J., Friedrich, M., Hemmen, K., et al. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00892-5
“ADHD is most often treated pharmacologically, with stimulant medications as first-line therapy and several non-stimulant agents available as alternatives, all aimed at reducing core symptoms and functional impairment rather than targeting causal pathomechanisms [24, 25].”
Metadata
- Authors
- Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B.
- Affiliations
- Uppsala University (SE)
- Corresponding author
- Schiöth, Helgi B.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-11-17
- Volume
- 13
- Pages
- 1066988-1066988
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC9713849
- OpenAlex
- W4309604196
- Cited by
- 111
- References
- 96
- Citations by year
- 2026: 24 · 2025: 51 · 2024: 24 · 2023: 12
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Brain Research Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Keywords
- attention deficit hyperactivity disorder, ADHD treatment, pharmacotherapy, non-pharmacological treatment, psychostimulants, methylphenidate, atomoxetine, guanfacine, clonidine, noradrenergic reuptake inhibitors, antidepressants, atypical antipsychotics, behavioral interventions, social skills training, meditation, hypnotherapy, sleep interventions, physical activity interventions, clinical trial trends, therapeutic target, complementary and alternative medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.